Earnings Report
ABBV: Earnings: AbbVie to Host Third-Quarter 2026 Earnings Conference Call
October 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 30, 2026
- Company
- AbbVie Inc. (ABBV)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Earnings Report
Earnings: AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- Company
- AbbVie Inc. (ABBV)
Other upcoming events for ABBV
Phase 1 StartPhase1_Start: A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses ofABBV-1162 in Healthy Subjects
Phase 3 StartPhase3_Start: A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Phase 3 StartPhase3_Start: A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Phase 3 StartPhase3_Start: A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff
Patent ExpiryPatent_Expiry: NDA206302